LGVN - Gene Therapy Pioneer Roger Hajjar MD Elected to Longeveron® Board of Directors | Benzinga
MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Roger Hajjar, MD, Director of the Gene and Cell Therapy Institute at Mass General Brigham, has been elected to the Longeveron Board of Directors. Dr. Hajjar is an internationally recognized scientist whose cardiac gene therapy discoveries have spurred clinical trials for heart failure, whose methodologies for cardiac-directed gene transfer are currently utilized by investigators around the world, and who was appointed as the inaugural director of the Gene and Cell Therapy Institute. Dr. Hajjar was elected at the Company's recent Annual Meeting of Stockholders.
"I am delighted to welcome Roger, and his tremendous experience as a scientist, academic, and operational executive, to the Board of Directors," said Joshua Hare, Co-founder, Chief Science Officer and Chairman of the Board at Longeveron. "His thought leadership in gene and cell therapy will bring significant value to Longeveron as we continue to advance Lomecel-B™, our proprietary, scalable, allogeneic cellular therapy being evaluated in multiple indications. I look forward to collaborating with him to ...